Quest Laboratories (NSE:QUESTLAB) Debt-to-Revenue : 0.06 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:QUESTLAB Quest Laboratories Ltd NSE:QUESTLAB
44 GF Score
Price ₹90.50
! 5 Warning Signs
View Full Analysis

What is Quest Laboratories Debt-to-Revenue?

Quest Laboratories NSE:QUESTLAB -0.28% 44 Debt-to-Revenue is 0.06 as of Mar. 2026. GuruFocus rates NSE:QUESTLAB with a GF Score™ of 44/100. The stock has 5 warning signs investors should review.

Debt-to-Revenue measures a company's ability to pay off its debt.

Quest Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was ₹70 Mil. Quest Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was ₹9 Mil. Quest Laboratories's annualized Revenue for the quarter that ended in Mar. 2026 was ₹1,260 Mil. Quest Laboratories's annualized Debt-to-Revenue for the quarter that ended in Mar. 2026 was 0.06.

Quest Laboratories Debt-to-Revenue Historical Data

* Premium members only.

The historical data trend for Quest Laboratories's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Quest Laboratories Debt-to-Revenue Chart

Quest Laboratories Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Debt-to-Revenue
Get a 7-Day Free Trial 0.05 0.07 0.06 0.29 0.07

Quest Laboratories Semi-Annual Data
Mar21 Mar22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only 0.06 0.00 0.25 0.34 0.06

NSE:QUESTLAB vs LLY, JNJ, ABBV: Debt-to-Revenue Comparison

For the Drug Manufacturers - General subindustry, Quest Laboratories's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Quest Laboratories Debt-to-Revenue vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Quest Laboratories's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Quest Laboratories's Debt-to-Revenue falls into.


NSE:QUESTLAB
44GF Score
Quest Laboratories Ltd NSE:QUESTLAB
Debt-to-Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Quest Laboratories Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Quest Laboratories's Debt-to-Revenue for the fiscal year that ended in Mar. 2026 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(69.759 + 9.094) / 1118.218
=0.07

Quest Laboratories's annualized Debt-to-Revenue for the quarter that ended in Mar. 2026 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(69.759 + 9.094) / 1260.34
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Mar. 2026) Revenue data.

Frequently Asked Questions Learn more about Debt-to-Revenue →
What does a Debt-to-Revenue of 0.06 mean?
Quest Laboratories (NSE:QUESTLAB) has a Debt-to-Revenue of 0.06 as of Mar. 2026.
Is Quest Laboratories' Debt-to-Revenue too high?
Quest Laboratories' current Debt-to-Revenue is 0.06. Overall, Quest Laboratories has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Quest Laboratories' Debt-to-Revenue compare to LLY and JNJ?
Quest Laboratories' Debt-to-Revenue of 0.06 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Revenue for a Drug Manufacturers company?
A good Debt-to-Revenue depends on the Drug Manufacturers industry context. However, Debt-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Revenue mean?
A high Debt-to-Revenue can signal that a stock is expensive relative to its fundamentals. Quest Laboratories's current Debt-to-Revenue is 0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest Laboratories stock overvalued right now?
Quest Laboratories (NSE:QUESTLAB) has a current Debt-to-Revenue of 0.06. The current Debt-to-Revenue is 0.06. Quest Laboratories' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Revenue calculated?
Debt-to-Revenue is calculated from a company's financial statements. For Quest Laboratories (NSE:QUESTLAB), the current Debt-to-Revenue is 0.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Quest Laboratories Business Description

Address Sector III, Plot No. 45, Pithampur Industrial Area, Opposite Kissan Pipe Unit 4, District Dhar, Pithampur, Dhar, MP, IND, 454775
Quest Laboratories Ltd is engaged in the business of manufacturing pharmaceutical formulations across a broad spectrum, including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and more. It produces various products, comprising ethical drugs, generic drugs, and over-the-counter drugs, and is also available in various forms such as tablets, liquid orals, oral dry powders, oral powders (ORS), ointments, and external liquids, among others. The company operates in a single segment of Drugs and Chemicals.
44GF Score

Get the complete analysis for NSE:QUESTLAB

Debt-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹90.50
Price